RxDoctor Payments Data

Marilee Meeler, PA

Medical · Key West, FLNPI 1063476950

Payments from drug & device makers

$1,249in general payments, 2019–2025

Across 39 payments — averaging $32.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$317
  • Silk Road Medical, Inc.$165
  • Penumbra, Inc.$146
  • Boston Scientific$119
  • Abbott$89
  • Astellas Pharma US Inc$73
  • plus $339 from 9 others

What the payments were for

  • Food & beverage$1,249100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,249 in reported general payments places this provider in the 60th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$20,918
Medicare patients
168
Services billed
268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide52$59,066
EliquisApixaban19$31,145
JardianceEmpagliflozin14$16,872
OzempicSemaglutide11$11,716
Breo ElliptaFluticasone/Vilanterol12$7,603
PaxlovidNirmatrelvir/Ritonavir25$4,288
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$3,980
SynthroidLevothyroxine Sodium19$2,631
Omeprazole83$1,503
Alprazolam180$1,288
Albuterol Sulfate HfaAlbuterol Sulfate64$1,166
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,059
Levothyroxine Sodium77$931
Escitalopram Oxalate52$895
Ezetimibe21$856

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$39$59,06652 claims
PfizerEliquis, Paxlovid$41$35,43344 claims
Novo NordiskOzempic$35$11,71611 claims
GSKBreo Ellipta$35$7,60312 claims
AbbVieSynthroid$317$2,63119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,031 medical providers in Florida.

Other medical in Key West

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →